New clinical trials data presented at ASCO 2011 revealed a striking response to drugs ipilimumab (recently-approved), and vemurafenib, a new drug for patients with the most common subtype of advanced melanoma (B-RAF V600E Mutation). Dr. Kim Margolin, a Melanoma specialist at the Fred Hutchinson Cancer Research Institute in Seattle helped us understand why this new drug is making news and why patients have reason to be hopeful.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…